导师风采
徐兵河
个人信息
Personal Information
- 性别：男
- 导师类型：博士生导师
- 职称：主任医师
- 该职称任职时间：19980606
联系方式
Contact Information
- 所属院系：肿瘤医院
- 所属专业：
- 邮箱 : xubinghe@medmail.com.cn
- 工作电话 : 87788826
个人简介
Personal Profile
中国工程院院士，主任医师，教授，博士生导师。毕业于北京协和医学院，曾赴美国迈阿密大学医学院从事博士后研究工作，曾担任中国医学科学院肿瘤医院内科主任，现任国家新药（抗肿瘤）临床研究中心（GCP中心）主任。徐院士是我国著名的肿瘤内科和乳腺癌专家，长期致力于肿瘤内科临床和相关基础研究、乳腺癌临床诊治与抗肿瘤新药研发。在分子分型与个体化治疗、肿瘤耐药、筛查早诊等方面做出了一系列开创性研究工作，解决了个体化诊疗领域多个难题，建立了个体化诊疗新方法、新模式和新策略，显著提高了患者生存率。徐院士也是我国恶性肿瘤新药开发及临床试验领域的领军人物，通过从建立临床试验平台到牵头国际和国内多中心临床试验和转化研究，推动了我国抗肿瘤新药创制及走向国际。徐院士担任中国抗癌协会肿瘤药物临床研究专业委员会主任委员，中国抗癌协会乳腺癌专业委员会名誉主任委员，中国医师协会内科医师分会副会长，中国医药教育协会肿瘤临床科研创新发展专业委员会主任委员，国家肿瘤质控中心乳腺癌专家委员会主任委员，国家抗肿瘤药物临床监测专家委员会主任委员，国家“重大新药创制”重大专项论证专家委员会成员。徐院士在国际上也享有盛誉，他是St. Gallen早期乳腺癌治疗国际专家共识指南团成员、晚期乳腺癌治疗国际专家共识指南团成员、ESMO（欧洲内科肿瘤学会）和ESCO（欧洲肿瘤学院）核心成员（Faculty member），ESMO早期乳腺癌临床实践指南执笔组成员，并担任《Lancet Oncology》杂志国际顾问委员会委员。以第一/通讯作者在Nature Medicine、Cancer Cell、Lancet Oncology、Journal of Clinical Oncology、Annals of Oncology、JAMA Oncology等国际著名期刊发表学术论文近200篇，主持编撰国家卫健委《乳腺癌诊疗规范》、《乳腺癌合理用药指南》等我国规范和指南20余部，主编教材及专著15部。
团队简介
Team Profile
待补充更新
- 研究方向Research Directions
肿瘤内科,乳腺癌的临床及转化研究
- 在校研究生Current Graduate Students
硕士研究生 1 名，博士研究生 8 名
- 科研项目Research Projects
| # | 项目名称 | 起止日期 | 金额 | 项目类型 | 本人角色 |
|---|---|---|---|---|---|
| 1 | 现代整合型医疗健康照护 体系与人才培养模式研究 | 2022-01-01 —— 2022-12-31 | 100.0 | 主持在研的国家或省部级科研项目 | 主持者 |
| 2 | 肿瘤临床试验专业化人才培育建设 | 2020-01-01 —— 2022-12-31 | 220.3 |
- 发表论文Papers
| # | 论文题目 | 期刊名称 | 发表年份 | 论文署名 |
|---|---|---|---|---|
| 1 | 微小RNA基因多态与乳腺癌易感性的关系 | 中华肿瘤杂志 | 2022-06-18 | 徐兵河 |
| 2 | Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study. | Breast Cancer Res Treat. 2020 Aug;182(3):689-697. | 2022-06-18 | 徐兵河 |
| 3 | Single-cell analyses reveal key immune cell subsets associated with response to PDL1 blockade in triple negative breast cancer | Cancer Cell, 2021, 39: 1-13 （IF 31.7） | 2022-06-18 | 徐兵河 |
| 4 | Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. | Ann Oncol，2013，24(5):1219-1225. （IF 32.9） | 2022-06-18 | 徐兵河 |
| 5 | Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. | Lancet Oncol, 2021; 22(3)：351-360 （IF 41.3） | 2022-06-18 | 徐兵河 |
| 6 | Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/ or Trastuzumab: A Randomized, Phase II Study. | J Clin Oncol, 2019，37(29): 2610-2619 （IF 44.5） | 2022-06-18 | 徐兵河 |
| 7 | Profile and outcome of receptor conversion in breast cancer metastases: a nation-wide multicenter epidemiological study | Int J Cancer. 2021，148(3):692-701. | 2022-06-18 | 徐兵河 |
| 8 | Mutational characteristics determined using circulating tumor DNA analysis in triple-negative breast cancer patients with distant metastasis | Cancer Communications.2020;1–5. | 2022-06-18 | 徐兵河 |
| 9 | Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China. | Cancer Communications.2020;40:260–269. | 2022-06-18 | 徐兵河 |
| 10 | fficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis | Breast Cancer Res Treat. 2018 Oct;171(3):535-544. | 2022-06-18 | 徐兵河 |
| 11 | Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial. | Ann Oncol, 2021, 32(2):218-228. （IF 32.9 ） | 2022-06-18 | 徐兵河 |
| 12 | Sex-Based Heterogeneity in the Clinicopathological Characteristics and Prognosis of Breast Cancer: A Population-Based Analysis | Front.Oncol.11:642450 | 2022-06-18 | 徐兵河 |
| 13 | Breast cancer in women younger than 25: clinicopathological features and prognostic factors | Ann Oncol. 2009，20(2):387-389.(IF:32.9)。 | 2022-06-18 | 徐兵河 |
| 14 | Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in China | Int J Cancer, 2020, Dec 15;147(12):3490-3499. | 2022-06-18 | 徐兵河 |
| 15 | The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial–mesenchymal transition markers in the frst-line chemotherapy of HER2-negative metastatic breast cancer | Cancer Commun, 2019, 39:1. | 2022-06-18 | 徐兵河 |
| 16 | First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers. | BMC Cancer (2019) 19:279. | 2022-06-18 | 徐兵河 |
| 17 | Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer. | Lancet Oncol，2016, 17(3):357-366. （IF 41.3） | 2022-06-18 | 徐兵河 |
| 18 | Safety and efficacy study of oral metronomic vinorelbine combined w ith trastuzumab (mNH) in HER2-positive metastatic breast cancer: a phase II trial | Breast Cancer Research and Treatment, 2021, 188(2): 441-447 | 2022-06-18 | 徐兵河 |
| 19 | Comparison of capecitabine-based regimens with platinum-based regimens in Chinese triple-negative breast cancer patients with liver metastasis. | Ann Transl Med. 2021 Jan;9(2):109 | 2022-06-18 | 徐兵河 |
| 20 | Metronomic therapy in advanced breast cancer and NSCLC: vinorelbine as a paradigm of recent progress. | Expert Rev Anticancer Ther. 2021 Jan;21(1):71-79. | 2022-06-18 | 徐兵河 |
| 21 | Characterization of functional excision repair cross complementation group 1 variants and their association with lung cancer risk and prognosis | Clin Cancer Res.2008,14(9): 2878-2886.(IF:10.199) | 2022-06-18 | 徐兵河 |
| 22 | Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours | Chemotherapy and Pharmacology | 2022-06-18 | 徐兵河 |
| 23 | Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes | Lancet Oncol, 2017, 17(3):357-366. （IF 41.3） | 2022-06-18 | 徐兵河 |
| 24 | Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human EGFR2-Positive Metastatic Breast Cancer. | J Clin Oncol，2017，35(27):310-316. （IF 44.5） | 2022-06-18 | 徐兵河 |
| 25 | Carboplatin plus taxanes are non？inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple？negative breast cancer. | Breast Cancer Research and Treatment (2020) 182:67–77. | 2022-06-18 | 徐兵河 |
| 26 | Tu mor-derived microparticles promote the progression of triple-negative breast cancer via PD-L1-ass ociated immune suppression | CANCER LETTERS, 2021, 523： 43-56 | 2022-06-18 | 徐兵河 |
| 27 | Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combinati on with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial | CLINICAL CANCER RESEARCH, 2019, 25(17): 5212-5220 | 2022-06-18 | 徐兵河 |
| 28 | Ganglioside Monosialic Acid Alleviates Peripheral Neuropathy Induced by Utidelone Plus Capecitabine in Metastatic Breast Cancer From a Phase III Clinical Trial | Front Oncol. 2020 Oct 9;10:524223. | 2022-06-18 | 徐兵河 |
| 29 | Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer | Int.J.Cancer:146,1359–1368 | 2022-06-18 | 徐兵河 |
| 30 | Neratinib-based therapy in patients with metastatic HER2-positive breast cancer from Asia. | Future Oncol | 2022-06-18 | 徐兵河 |
| 31 | Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial. | Cancer Commun (2019) 39:16. | 2022-06-18 | 徐兵河 |
| 32 | HER2阳性晚期乳腺癌靶向治疗耐药与预后关系的真实世界研究 | 中华肿瘤杂志 | 2022-06-18 | 徐兵河 |
| 33 | Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10T/T genotype breast cancer patients in China | Int J Cancer.2018,143(10):2499-2504.(IF:7.36) | 2022-06-18 | 徐兵河 |
| 34 | Chinese Expert Consensus on the Clinical Diagnosis and Treatment of Advanced Breast Cancer (2018) | Cancer, 2020;126:3867-3882. | 2022-06-18 | 徐兵河 |
| 35 | Targeted therapeutic options and future perspectives for HER2-positive breast cancer | Signal Transduction and Targeted Therapy. 2019, 4:34. | 2022-06-18 | 徐兵河 |
| 36 | Dalpiciclib or placebo plus fulvestrant in pretreated hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 study | Nature Medicine，2021, 7（11）: 1904-1910 （IF 55.4） | 2022-06-18 | 徐兵河 |
| 37 | Primary Trastuzumab Resistance After (Neo)adjuvant Trastuzumab-containing Treatment for Patients With HER2-positive Breast Cancer in Real-world Practice | Clin Breast Cancer. 2020 Dec 16:S1526-8209(20)30218-4. | 2022-06-18 | 徐兵河 |
| 38 | DNA damag e response as a prognostic indicator in metastatic breast cancer via mutational analysis | Annals of Translational Medicine, 2021, 9(3): 220-231 | 2022-06-18 | 徐兵河 |
| 39 | The molecular tumor burden inde x as a response evaluation criterion in breast cancer | Signal Transduction and Targeted Therapy, 2021, 6(1): 251-259（IF 18.1)） | 2022-06-18 | 徐兵河 |
| 40 | Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective. Breast Cancer | Targets and Therapy 2021:13 135–150. | 2022-06-18 | 徐兵河 |
| 41 | Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators A Phase 2 Randomized Clinical Trial | JAMA Oncol，2021, 7(10): E1-E7 （IF 31.7） | 2022-06-18 | 徐兵河 |
| 42 | HER2-targeted regimens after prior trastuzumab for patients with HER2-positive unresectable, locally advanced or metastatic breast cancer: a network meta-analysis of randomized controlled trials | Ann Transl Med. 2020 Dec;8(24):1634. | 2022-06-18 | 徐兵河 |
| 43 | Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma | Clin Cancer Res.2018,24(6):1296-1304.(IF:10.199) | 2022-06-18 | 徐兵河 |
| 44 | 乳腺癌脑转移的基因突变特征及靶向治疗 | 国际肿瘤学杂志 | 2022-06-18 | 徐兵河 |
| 45 | Reactive capillary hemangiomas: a novel dermatologictoxicity following anti-PD-1 treatment with SHR-1210. | Cancer Biol Med. 2019; 16: 173-80. | 2022-06-18 | 徐兵河 |
| 46 | 高复发风险早期乳腺癌患者行表阿霉素联合环磷酰胺序贯紫杉醇剂量密集辅助化疗的耐受性分析 | 中华肿瘤杂志 | 2022-06-18 | 徐兵河 |
| 47 | Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China | Front Oncol. 2021 Feb 11;10:599604. | 2022-06-18 | 徐兵河 |
| 48 | Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer | Chin J Cancer Res. 2020 Aug;32(4):485-496. | 2022-06-18 | 徐兵河 |
| 49 | Current Clinical Trials on Breast Cancer in China: A Systematic Literature Review | Cancer, 2020;126:3811-3818. | 2022-06-18 | 徐兵河 |
| 50 | The relationship between the CYP2D6 p olymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Ch inese Han population | INTERNATIONAL JOURNAL OF CANCER, 2018, 143(：): 184-189 | 2022-06-18 | 徐兵河 |
| 51 | 乳腺外实体瘤乳腺转移患者的临床病理特征和预后 | 中华肿瘤杂志 | 2022-06-18 | 徐兵河 |
- 科研获奖Research Awards
| # | 获奖证书编号 | 奖项名称 | 获奖级别 | 获奖类别 | 获奖等级 | 获奖日期 | 颁奖单位 | 本单位是否为第一完成单位 | 完成单位排名 | 本人排序 | 备注 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | - | 全国创新争先奖（基础与研究探索） | 国家级 | 其他国家级奖励 | 其他 | 2020-05-01 | 中华人民共和国科学技术 | 是 | 1 | 1 | |
| 2 | 2015-257 | 局部晚期与转移性乳腺癌治疗关键技术研究及应用 | 省部级 | 科技进步奖、哲学社科奖 | 二等奖 | 2016-02-26 | 中华人民共和国教育部 | 是 | 1 | 1 | |
| 3 | K-1102-2-10-1 | 恶性肿瘤个体化的临床与基础研究 | 省部级 | 科技进步奖、哲学社科奖 | 二等奖 | 2012-09-06 | 中国抗癌协会 | 是 | 1 | 1 | |
| 4 | 2012医-2-005-01 | 评价肿瘤风险与治疗反应的遗传标志物研究及其应用 | 省部级 | 科技进步奖、哲学社科奖 | 二等奖 | 2012-12-01 | 北京市政府 | 是 | 1 | 1 | |
| 5 | - | 中国大学出版社图书奖首届优秀学术著作奖 | 省部级 | 其他省部级奖励 | 一等奖 | 2022-12-01 | 中华人民共和国教育部 | 是 | 1 | 1 | |
| 6 | 201501013P1501 | 乳腺癌个体化诊疗关键技术研究及应用 | 省部级 | 科技进步奖、哲学社科奖 | 一等奖 | 2016-11-25 | 中国医疗保健国际交流促进会 | 是 | 1 | 1 | |
| 7 | K-1502-1-2-1 | 局部晚期与转移性乳腺癌治疗关键技术研究及应用 | 省部级 | 科技进步奖、哲学社科奖 | 一等奖 | 2016-10-14 | 中国抗癌协会 | 是 | 1 | 1 | |
| 8 | 2019-J-233-2-03-D01 | 乳腺癌精准诊疗关键技术创新与应用 | 国家级 | 国家最高科学技术奖、自然科学奖、技术发明奖、科技进步奖 | 二等奖 | 2019-12-18 | 中华人民共和国国务院 | 是 | 1 | 1 |
- 研究成果Research Findings
| # | 成果类型 | 项目/专利/新品种名称 |
|---|---|---|
| 1 | 作为主创人员获得授权的发明专利和新品种 | SNP标志物在预测TAM辅助内分泌治疗乳腺癌患者疗效中的应用 |
| 2 | 作为主创人员获得授权的发明专利和新品种 | 一种检测外周血TCR可变区编码基因的液体活检试剂盒及其应用 |
| 3 | 作为主创人员获得授权的发明专利和新品种 | 一种判断曲妥珠单抗辅助治疗乳腺癌疗效的试剂盒及应用专利 |
| 4 | 作为主创人员获得授权的发明专利和新品种 | 预测乳腺癌患者对吡咯替尼治疗反应的性的生物标记物 |
| 5 | 作为主创人员获得授权的发明专利和新品种 | PTCH2基因突变位点在判断年轻乳腺癌易感性中的应用 |
| 6 | 作为主创人员获得授权的发明专利和新品种 | miR-6734-5p在制备Luminal型乳腺癌诊断工具中的应用 |
| 7 | 作为主创人员获得授权的发明专利和新品种 | 利用TRBV家族成员预测曲妥珠单抗新辅助治疗乳腺癌患者疗效试剂盒及其应用 |
| 8 | 作为主创人员获得授权的发明专利和新品种 | 一种预测乳腺癌对曲妥珠单抗联合化疗治疗敏感性的生物标记物 |
| 9 | 作为主创人员获得授权的发明专利和新品种 | 一种检测P53基因SNP位点的试剂及其应用 |
| 10 | 作为主创人员获得授权的发明专利和新品种 | 手足综合症易感性检测试剂盒和SNP在其制备中的应用 |
| 11 | 出版高水平专著 | 《应对乳腺癌专家谈》 |
| 12 | 出版高水平专著 | 《简明临床肿瘤学》 |
| 13 | 出版高水平专著 | 《HER2阳性乳腺癌》 |
| 14 | 出版高水平专著 | 《乳腺癌全方位全周期健康管理》 |
| 15 | 出版高水平专著 | 《乳腺肿瘤学》 |
| 16 | 出版高水平专著 | 《乳腺癌》 |
| 17 | 出版高水平专著 | 《肿瘤遗传咨询》 |
| 18 | 出版高水平专著 | 《乳腺癌靶向治疗原则与临床实践》 |